Semaglutide administration reduces voluntary caloric intake by approximately 24%

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Supports users in reaching and maintaining a healthy body weight through behavioral and nutritional tools.